Genmab A/s

Organisation

Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

Headquarters

2973

Employees

Health Technology

Industry

Jan van de Winkel

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Price

Target

Genmab A/s (GMAB) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Genmab A/s (GMAB) share price will touch around $37.65 in next 12-months.

Currently 31 wall-street analysts regularly analyze the financials of Genmab A/s on a frequent basis to provide recommendations along with target share price. 31 analysts offering 12-month price forecasts for Genmab A/s (GMAB) have a share price target of $37.65. This median of share price forecast represents a 46.96% upside from the latest price of $25.62 as on 20.03.26.

Genmab A/s (GMAB) Share Price Forecast

Home

US Stocks

Genmab A/s (GMAB)

Genmab A/s Stock Forecast

Genmab A/s Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Genmab A/s (GMAB): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Genmab A/s's share price and its median forecast price. As on 20.03.26, the difference is -16.99%

Genmab A/s Forecast and Target Price

Genmab A/s (GMAB) Share Price Forecast

Genmab A/s (GMAB) Price vs Consensus Price Target

Genmab A/s (GMAB) Share Price Forecast v/s Share Price Today

Genmab A/s (GMAB): Difference between Current Price & Median Forecasted Price

Genmab A/s (GMAB) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price